INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

ATHEALTERITY THERAPEUTICS LTD

CIK 0001131343

EDGAR filingsOpen in network
Disclosed transactions5
Buys / sells3 / 0
Max Insider Score56
Connections5with evidence

ATHE · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
52
MA
Marks Peter AshleyDirector
ATHEALTERITY THERAPEUTICS LTD
Open-market purchase
BUY$24K
47.6K sh
Aug 31, 2026Sep 8, 2026
traded Aug 31, 2026
+8dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Stamler David AllenDirector, Chief Executive Officer · Sep 8, 2026
  • ← Insider ofevidence
    Marks Peter AshleyDirector · Sep 8, 2026
  • ← Insider ofevidence
    Babarczy Julian MichaelDirector · Jun 23, 2026
  • ← Insider ofevidence
56
SA
Stamler David AllenDirector, Chief Executive Officer
ATHEALTERITY THERAPEUTICS LTD
Open-market purchase
BUY
$24K
47.6K sh
Aug 31, 2026
Sep 8, 2026
traded Aug 31, 2026
+8d
SEC FORM 4

Evidence

56
MA
Marks Peter AshleyDirector
ATHEALTERITY THERAPEUTICS LTD
Open-market purchase
BUY$24K
47.6K sh
Aug 31, 2026Sep 8, 2026
traded Aug 31, 2026
+8dSEC FORM 4

Evidence

19
BM
Babarczy Julian MichaelDirector
ATHEALTERITY THERAPEUTICS LTD
Grant or award
A—
2.00M sh
Jun 15, 2026Jun 23, 2026
traded Jun 15, 2026
+8dSEC FORM 4

Evidence

19
GB
Gozlan Lawrence BernardDirector
ATHEALTERITY THERAPEUTICS LTD
Grant or award
A—
1.00M sh
Jun 15, 2026Jun 23, 2026
traded Jun 15, 2026
+8dSEC FORM 4

Evidence

Gozlan Lawrence Bernard
Director · Jun 23, 2026